Member Info for daveycaferacer

Two things particularly interest me at the moment during my regular musings:- 1. No specific update on LIlly's option to take up global rights to Frquintinib, so I've come to the conclusion they must have deferred for a year (although that is probably less than 8 months to go to the next decision milestone) 2. AZ still have Savolitinib PRCC down under PII on the pipeline but it is in PIII (their website was last update on the 27th July so maybe they just missed the latest update) Lots of news due. In the meantime I'd advise people to look at the Company website regularly as various items get posted such as the Medical Innovations summit content I mentioned below.

https://www.rsm.ac.uk/medical-innovations/future-summit.aspx

http://www.chi-med.com/royal-society-of-medicine-summit/ New Presentation on the Company website which includes some new content on the cancer landscape in China

Bernie, well married in 1986 but my wife died of breast cancer in 2009, and stupidly I got married again............hmmm My wife always attends the AGM with me and she has a vested interest in the Company's continued success.

ah yes Matt, well, I lived in the bible belt in Atlanta Georgia for a few years which was life changing! I take a keen interest in American Biotechs with small positions in Tesaro, Kite, and Juno, some of which are named in our presentation deck, but my real interest (my wife says it's bordering pon obsession) is Chi-Med. Lots and lots of news due, some material.

thanks Matt, I am aware of that - 2 x ADR's = 1 Ordinary share. I have a 401K pension in the United States so already have assets there and want to continmue to build assets in both places, that's the reason for buying both ADR's and shares. I also have a house in the U.S. and a U.S. bank account etc

clearly I got that wrong if convcerting back to sterling. Anyway I continue to buy mainly on AIM but like a bit of currency risk by buying ADR's too. No brexit deal on trade by March is looking increasingly likely which will tank the pund again, even if interest rates rise.

At least my ADR's have effectively gone up in value! There is a huge amount of news due.....

yes, the master trick pulled off by the majority of Private Investors is to buy at the peaks and sell at the lows.....I suspect this is a low point because thefundamentals suggest that to be the case. Yes there is debt but it's well covered, and we already know coal prices will fall into 2019 which will go straight to the bottom line here. A great entry point for anyone with a medium to long term timeframe.

http://www.proactiveinvestors.co.uk/companies/news/183527/natixis-upgrades-astrazeneca-to-buy-on-prospect-of-positive-results-from-key-mystic-lung-cancer-trial-183527.html "Full data presentations on studies for lung cancer drugs Tagrisso and Imfinzi are expected this month" An interesting and positive update which could be helpful for our combination setting

Dar- factually you are correct at the moment but you ommit to mention the ongoing SFO investigation. Once concluded you may find things change somewhat....

my point exactly

"So in effect Rob Terry and the BoD of quindell are not liable for losses made by pi's" You assume that the Directors did not mislead the market or put out false information. If they didn't do that then you are correct. If they did then you are not correct.

I will be buying substantially sub 20p

Interesting update on Lillty in China Lilly Asia Ventures Closes Fourth Fund with $450 Million publication date: Aug 15, 2017 View a Printer Friendly version of this page, allowing you to print the page. Lilly Asia Ventures has closed its fourth China/Asia life science-focused fund at $450 million, a hard cap, according to China Money Network. This is over three times the $100 million of its previous fund, which closed in 2015. The new fund, known as LAV Biosciences Fund IV, took only two months to reach its cap, and was "significantly oversubscribed." Lilly, a company that is active in diabetes and cancer treatment, got its start in Asia/China venture capital with a $10 million investment in the BioVeda China fund in 2007, the first international VC fund dedicated to making life science investments in China. More details....

I wonder how the SFO are getting on.......

NASDAQ Biotech Index continues to rally strongly, probably helped by all the mega deals and rumpurs of mega deals such as Gileads bid for Kite Pharma....... https://indexes.nasdaqomx.com/Index/History/NBI

Thanks for summarising Warwis, and clearly our Chairman and the Directors think the Company is still good value even at today's price. Just reminding myself of what Mr To said at the time of the interims:- "“Chi-Med’s consistent strategy over the past 16 years has generated considerable shareholder value, and we believe it is now poised to deliver substantially more."" I interpret that as saying, if you think the last 10 years growth has been fantastic look at the next 10 years...

The co. has debt but is profitable, generates cash and is moving into renewables with free input costs eg. Sunlight If it cam get a handle on its coal costs by more effectively managing future contracts and hedging then it has a bright future. In the meantime it would be useful in management issued a further statement on how it intends to manage input costs. Whilst I accept it has no control over world coal prices, there are ways to manage input costs and to mitigate against rises.

Just like PFG and DC last week, this has been way overdone IMO. As always the case, stocks drop like a stone on bad or poor news but take a long time to recover to a sensible position. I continue to buy.